Leconotide

• CAT Number: I030610
• CAS Number: 247207-64-3
• Molecular Formula: C107H179N35O36S7
• Molecular Weight: 2756.24
• Purity: 98%
• Synonyms: Leconotide; AM 336; AM336; AM-336; CNSB-004; CNSB 004; CNSB004
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (6S,12S,15S,21S,24R,27S,33S,36R,39R,42S)-1-amino-6-(((R)-1-amino-1-oxo-3-thioxopropan-2-yl)carbamoyl)-42-((2S,5S,8S,11S,14S,17R,20S,23S,29S,32S,35S,38R)-38-amino-11,20,29,35-tetrakis(4-aminobutyl)-2-(4-hydroxybenzyl)-14,32-bis(hydroxymethyl)-8-isobutyl-39-mercapto-17-(mercaptomethyl)-23-methyl-5-(2-(methylthio)ethyl)-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaazanonatriacontanamido)-15-((R)-1-hydroxyethyl)-21,27,33-tris(hydroxymethyl)-1-imino-12-isopropyl-39-(mercaptomethyl)-8,11,14,17,20,23,26,29,32,35,38,41-dodecaoxo-24,36-dithioformyl-2,7,10,13,16,19,22,25,28,31,34,37,40-tridecaazatetratetracontan-44-oic acid
• InChI: InChI=1S/C107H179N35O36S7/c1-51(2)33-64(129-91(163)62(20-11-15-30-111)127-100(172)71(44-147)135-103(175)73(47-181)137-93(165)60(18-9-13-28-109)124-85(157)53(5)121-77(150)36-117-87(159)58(17-8-12-27-108)126-99(171)70(43-146)134-92(164)61(19-10-14-29-110)125-86(158)57(112)45-179)95(167)128-63(26-32-185-7)94(166)130-65(34-55-22-24-56(149)25-23-55)96(168)131-66(35-81(154)155)97(169)138-76(50-184)104(176)140-75(49-183)102(174)133-67(40-143)88(160)118-37-79(152)123-69(42-145)98(170)139-74(48-182)101(173)132-68(41-144)89(161)119-39-80(153)141-83(54(6)148)106(178)142-82(52(3)4)105(177)120-38-78(151)122-59(21-16-31-116-107(114)115)90(162)136-72(46-180)84(113)156/h22-25,46,48-49,51-54,57-76,82-83,143-149,179,181,184H,8-21,26-45,47,50,108-112H2,1-7H3,(H2,113,156)(H,117,159)(H,118,160)(H,119,161)(H,120,177)(H,121,150)(H,122,151)(H,123,152)(H,124,157)(H,125,158)(H,126,171)(H,127,172)(H,128,167)(H,129,163)(H,130,166)(H,131,168)(H,132,173)(H,133,174)(H,134,164)(H,135,175)(H,136,162)(H,137,165)(H,138,169)(H,139,170)(H,140,176)(H,141,153)(H,142,178)(H,154,155)(H4,114,115,116)/t53-,54+,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,82-,83-/m0/s1
• InChIKey: HBMCYCKNGADUQP-CFIKXUEXSA-N
• SMILES: CSCC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N)=O)C=S)=O)CCCNC(N)=N)=O)=O)C(C)C)=O)[C@H](O)C)=O)=O)CO)=O)C=S)=O)CO)=O)=O)CO)=O)C=S)=O)CS)=O)CC(O)=O)=O)Cc1ccc(O)cc1)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CS)N)=O)CCCCN)=O)CO)=O)CCCCN)=O)=O)C)=O)CCCCN)=O)CS)=O)CO)=O)CCCCN)=O)CC(C)C)=O

Leconotide (Cat No.: I030610) is a synthetic peptide derived from the venom of marine cone snails, designed as a potent and selective blocker of N-type voltage-gated calcium channels (Cav2.2). By inhibiting calcium influx in neurons, it reduces neurotransmitter release and provides strong analgesic effects, making it a promising candidate for managing chronic and neuropathic pain. Leconotide is structurally related to ziconotide but is engineered for improved stability and pharmacokinetics. It is primarily used in preclinical research focused on non-opioid pain therapies and neuropharmacology.

Reference

1: Bruel BM, Burton AW. Intrathecal Therapy for Cancer-Related Pain. Pain Med. 2016 Dec;17(12):2404-2421. doi: 10.1093/pm/pnw060. Epub 2016 Apr 28. PMID: 28025375; PMCID: PMC5654346.
2: Zamponi GW, Striessnig J, Koschak A, Dolphin AC. The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacol Rev. 2015 Oct;67(4):821-70. doi: 10.1124/pr.114.009654. PMID: 26362469; PMCID: PMC4630564.
3: Deer TR, Pope JE, Hanes MC, McDowell GC. Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options. Pain Med. 2019 Apr 1;20(4):784-798. doi: 10.1093/pm/pny132. PMID: 30137539; PMCID: PMC6442748.
4: Kolosov A, Goodchild CS, Cooke I. CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010 Feb;11(2):262-73. doi: 10.1111/j.1526-4637.2009.00741.x. Epub 2009 Nov 25. PMID: 20002322.
5: Wie CS, Derian A. Ziconotide. 2020 Jul 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 29083772.
6: Kolosov A, Aurini L, Williams ED, Cooke I, Goodchild CS. Intravenous injection of leconotide, an omega conotoxin: synergistic antihyperalgesic effects with morphine in a rat model of bone cancer pain. Pain Med. 2011 Jun;12(6):923-41. doi: 10.1111/j.1526-4637.2011.01118.x. Epub 2011 May 3. PMID: 21539704.
7: Dupoiron D. Intrathecal therapy for pain in cancer patients. Curr Opin Support Palliat Care. 2019 Jun;13(2):75-80. doi: 10.1097/SPC.0000000000000427. PMID: 30896454.
8: Viswanath O, Urits I, Burns J, Charipova K, Gress K, McNally A, Urman RD, Welschmeyer A, Berger AA, Kassem H, Sanchez MG, Kaye AD, Eubanks TN, Cornett EM, Ngo AL. Central Neuropathic Mechanisms in Pain Signaling Pathways: Current Evidence and Recommendations. Adv Ther. 2020 May;37(5):1946-1959. doi: 10.1007/s12325-020-01334-w. Epub 2020 Apr 10. PMID: 32291648; PMCID: PMC7467462.
9: Deer TR, Pope JE, Hayek SM, Lamer TJ, Veizi IE, Erdek M, Wallace MS, Grider JS, Levy RM, Prager J, Rosen SM, Saulino M, Yaksh TL, De Andrés JA, Abejon Gonzalez D, Vesper J, Schu S, Simpson B, Mekhail N. The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks. Neuromodulation. 2017 Feb;20(2):155-176. doi: 10.1111/ner.12579. Epub 2017 Jan 2. PMID: 28042914.
10: Strigenz T. Ziconotide. J Pain Palliat Care Pharmacother. 2014 Mar;28(1):73-4. doi: 10.3109/15360288.2013.864749. Epub 2014 Jan 7. PMID: 24397285.